Catalyst Event
Shanghai Junshi Biosciences Co Ltd (1877) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
5/26/2026, 12:00:00 AM
On 2026-05-26, the company announced that the final analysis of its Phase III NEOTORCH study for toripalimab plus chemotherapy met its primary endpoints; a supplemental new drug application submission (Estimated >10% impact due to major clinical success in NSCLC) is expected.
Korean Translation
2026-05-26, 회사의 테리프리맙(toripalimab) III상 임상(NEOTORCH 연구) 최종 분석 결과 주요 평가변수 충족 및 보충 신약 허가 신청서 제출이 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q2 2026 earnings release and conference call. Medium importance is estimated as earnings releases typically cause >5% price volatility scheduled.
8/5/2026, 12:00:00 AM
Boston Scientific Corp (BSX) · Earnings Release
The Q2 2026 earnings release scheduled for 2026-07-29, for which high importance is estimated due to typical market volatility surrounding quarterly results, is expected.
7/29/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Earnings Release
Q2 2026 earnings release is scheduled for July 16, 2026; a price impact of at least 5% is estimated based on historical volatility, scheduled.
7/16/2026, 12:00:00 AM
Hansoh Pharmaceutical Group Company Limited (3692) · Other
Final dividend of HKD 0.20 per share ex-dividend on July 3, 2026; standard corporate action with minor price adjustment scheduled.
7/3/2026, 12:00:00 AM
CSPC Pharmaceutical Group Ltd (1093) · Other
Ex-dividend date for the 2025 final dividend of HK$0.15 per share, which was announced on March 25, 2026. The payment date is July 15, 2026.
6/24/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Other
Ex-dividend date (2026-06-19) for a proposed record-high annual dividend of CHF 4.70 per share; impact estimated at ~2% as dividend is record-high, scheduled.
6/19/2026, 12:00:00 AM